Philip Sclafani: Will PBM Reform Actually Lower Net Drug Costs?

Pharmaceutical Commerce· June 19, 2026

Philip Sclafani examines the ongoing debate surrounding Pharmacy Benefit Manager (PBM) reform and its potential to reduce net drug costs. As policymakers scrutinize the role of PBMs in the pharmaceutical supply chain, the industry is closely watching for shifts in rebate structures and pricing transparency. Understanding these regulatory trends is essential for pharmaceutical manufacturers and payers as they assess the future of drug affordability and market access.

Read the full story at Pharmaceutical Commerce

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Pharmaceutical Commerce.

More in Pharmaceutical

Popular antidepressant recalled for high levels of a potentially cancer-causing chemical

Breckenridge Pharmaceutical has issued a recall for nearly 360,000 bottles of duloxetine, a generic version of the antidepressant Cymbalta, due to the presence of potentially carcinogenic chemicals. The U.S. Food and Drug Administration (FDA) reported that the medication contained elevated levels of nitrosamines, which may increase the risk of cancer over time. This recall underscores the pharmaceutical industry's ongoing struggle with impurity management in generic drug production and the critical role of regulatory oversight in maintaining patient safety.

June 21, 2026

Times Opinion: A transparent ruse against reproductive rights

Times Opinion: A transparent ruse against reproductive rights Chattanooga Times Free Press

June 21, 2026

US Launches Investigation into Drug Prices in Germany, Risking Renewed Tensions with Europe

The United States government has initiated a formal investigation into Germany's pharmaceutical pricing policies, alleging that the country’s healthcare system systematically underpays for innovative medicines. This move by the Trump administration aims to address claims that European price regulations force pharmaceutical companies to charge higher prices in the U.S. market to recoup research and development costs. For the pharmaceutical sector, this escalation signals a significant shift in trade relations that could impact global pricing strategies and market access across the European Union.

June 21, 2026

FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps

The U.S. Food and Drug Administration has highlighted a recall of duloxetine, drawing attention to persistent quality gaps in generic drug manufacturing. This development serves as a reminder of the regulatory pressures facing generic producers to ensure consistency and safety in their production processes. The situation is significant for the pharmaceutical industry as it emphasizes the potential risks associated with manufacturing oversight in the generic market.

June 20, 2026